Source · Select Committees · Public Accounts Committee
Recommendation 14
14
Acknowledged
Lack of long-term funding certainty for drug strategy poses risks for local bodies.
Conclusion
While the strategy has a 10-year timescale to achieve its intended outcomes, its funding allocations are restricted to government Spending Review periods, typically for two to four years.42 When asked about how they could provide greater assurance to local bodies on longer-term funding, departments told us they were unable to do this because “that is not how spending reviews work” and that the existence of a 10-year strategy “was the best reassurance that we can give”.43 Ms Wiseman told us that the lack of longer-term certainty posed risks for local authorities and implementing bodies, especially in their ability to plan for the long-term and recruit the best people. When they are only able to 33 Qq 55, 58 34 Q 4; C&AG’s Report para 2.12 35 Q 23 36 Qq 15,31 37 Q 124 38 C&AG’s Report paras 13, 2.10 39 Qq 33, 88 40 Qq 32–35 41 Committee of Public Accounts, Alcohol treatment services, Fifty-Fourth Report of Session 2022–23, 24 May 2023, para 13 42 Background to the 2020 Spending Review – House of Commons Library (parliament.uk) 43 Qq 87, 93 12 Reducing the harm from illegal drugs offer 12-month contracts, it is difficult to recruit and train staff to work with the most vulnerable people in society, and there is a need to offer contracts beyond 2025 to enable people to develop careers in the sector.44
Government Response Summary
The government acknowledges the committee's concerns about long-term funding, explaining that spending reviews dictate allocations and that work is ongoing to develop a strong case for investment beyond March 2025.
Government Response
Acknowledged
HM Government
Acknowledged
3.4 As the Committee are aware, HM Treasury carries out spending reviews to determine how to spend public money, usually over a multi-year period, in line with the government’s priorities and wider fiscal position. The government continues to reiterate its commitment to delivery of the 10-year ambition set out in the Drug Strategy and work is ongoing to develop a strong case for investment beyond March 2025, including by commissioning impact and economic evaluations of the treatment and recovery portfolio.